Cargando…
Neutrophil-to-lymphocyte ratio predicts survival in European patients with hepatocellular carcinoma administered sorafenib
Neutrophil-to-lymphocyte ratio (NLR) is considered a prognostic factor in patients with hepatocellular carcinoma (HCC). Our aim is to investigate the prognostic significance of NLR in patients with HCC treated with sorafenib. RESULTS: Median follow-up time was 7 months. Patients were mostly in the i...
Autores principales: | Lué, Alberto, Serrano, Maria Trinidad, Bustamante, Francisco Javier, Iñarrairaegui, Mercedes, Arenas, Juan Ignacio, Testillano, Milagros, Lorente, Sara, Gil, Cristina, de la Torre, Manuel, Gomez, Alexandra, Sangro, Bruno |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732712/ https://www.ncbi.nlm.nih.gov/pubmed/29262546 http://dx.doi.org/10.18632/oncotarget.21528 |
Ejemplares similares
-
Malignant epithelioid hemangioendothelioma of the liver successfully treated with Sorafenib
por: Sangro, Bruno, et al.
Publicado: (2012) -
Pneumatocele during sorafenib therapy: first report of an unusual complication
por: Sangro, Paloma, et al.
Publicado: (2017) -
Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study
por: de la Torre-Aláez, Manuel, et al.
Publicado: (2022) -
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Outcomes in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Plus Sorafenib
por: Zhang, Lei, et al.
Publicado: (2021) -
Corrigendum: Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Outcomes in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Plus Sorafenib
por: Zhang, Lei, et al.
Publicado: (2021)